《大行報告》花旗上調創科(00669.HK)目標價至153元 評級「買入」
花旗發表研究報告指,創科(00669.HK)的直接競爭對手SWK預測2021年每股盈利將增長增長11%,高於預期的9%,指出在疫情爆發後創科及SWK均迅速鞏固市場地位,去年銷售增長大大高於行業增長,因此將創科2021至2022年的盈利預測上調1%至3%。
該行預期,去年下半年盈利將按年增長20%,增幅高於上半年的16%,其中佔總收入貢獻一半的專業工具業務,在利潤率增長的推動下,下半年收入增長料加快至27%;家居DIY及戶外園藝工具品牌RYOBI的增長則受居家需求疲軟影響,預期由上半年的15%,溫和回落至10%。
花旗指,創科的股價日前受拜登刺激政策延期所拖累而下跌,為投資者提供入市機會,將目標價由128元上調至153元,為2022年預測市盈率的約33倍,予「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.